{
    "clinical_study": {
        "@rank": "109366", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "PF-06342674", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and\n      immunogenicity of multiple doses of PF-06342674.  Several dose levels will be evaluated."
        }, 
        "brief_title": "A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women and men age 18 and older.\n\n          -  Diagnosis of type 1 diabetes within 2 years of randomization.\n\n          -  Peak stimulated C-peptide levels \u2265 0.15 ng/mL.\n\n        Exclusion Criteria:\n\n          -  Anticipated ongoing use of diabetes medications other than insulin.\n\n          -  Evidence or history of diabetic complications with significant end-organ damage.\n\n          -  Episode of severe hypoglycemia within 60 days of randomization.\n\n          -  Multiple hospitalizations for diabetic ketoacidosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038764", 
            "org_study_id": "B4351003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-06342674", 
                "description": "Multiple SC Doses", 
                "intervention_name": "PF-06342674 Dose A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PF-06342674", 
                "description": "Multiple SC Doses", 
                "intervention_name": "PF-06342674 Dose B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PF-06342674", 
                "description": "Multiple SC Doses", 
                "intervention_name": "PF-06342674 Dose C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PF-06342674", 
                "description": "Multiple SC Doses", 
                "intervention_name": "PF-06342674 Dose D", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "RN168", 
            "Adults", 
            "Type 1 Diabetes", 
            "T1D"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4351003&StudyName=A%20Study%20To%20Assess%20The%20Safety%20Of%20PF-06342674%20In%20Adults%20With%20Type%201%20Diabetes"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30318"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Pf-06342674 (rn168) in Adults With Type 1 Diabetes", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose limiting or intolerable treatment related AEs", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Incidence of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Incidence and severity of hypoglycemic events", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Incidence of abnormal laboratory findings", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Incidence of anti-drug antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Severity of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Causal relationship of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "127 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.", 
                "measure": "Volume of Distribution at Steady State (Vss)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }, 
            {
                "measure": "Accumulation ratio (R)", 
                "safety_issue": "No", 
                "time_frame": "127 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}